Exelixis

Genomics-based drug discovery company

Based in CA

🤖

AI Overview

With $1.4M in lobbying spend across 23 quarterly filings, Exelixis is a significant lobbying presence.

$1.4M
Total Lobbying Spend
23
Quarterly Filings
1
Lobbying Firms Used
4
Individual Lobbyists

Spending by Year

YearLobbying Spend
2020$240K
2021$180K
2022$360K
2023$240K
2024$180K
2025$180K

Lobbying Firms

THORN RUN PARTNERS

What They Lobby For

  • Issues related to pharmaceutical pricing.
  • Issues related to the promotion of research and development. H.R. 6201, Families First Coronavirus Response Act; S. 3548, Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.
  • Issues related to the promotion of research and development.
  • Issues related to the promotion of research and development of prescription medications.
  • Issues related to the promotion of research and development of prescription medications and policies considered for inclusion in Congress Build Back Better proposals.
  • Issues related to the promotion of research and development of prescription medications and policies considered for inclusion in the Build Back Better Act.
  • Issues related to the promotion of research and development of prescription medications and policies considered for inclusion in H.R.5376 - Inflation Reduction Act of 2022.
  • Issues related to the promotion of research and development of prescription medications and policies.
  • Tracking implementation of prescription drug pricing policies included as part of the Inflation Reduction Act (IRA).
  • Engagement with Congress on other possible policies that would hinder research and development of new medications.

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.